突变型p53与其合成致死基因的研究进展

doi:10.16288/j.yczz.14-277

遗传 ›› 2015, Vol. 37 ›› Issue (4): 321-326.doi: 10.16288/j.yczz.14-277

突变型p53与其合成致死基因的研究进展

刘同阳^1,2,郭海强²,朱美妍²,黄英泽²,贾舒婷²,罗瑛²,张继虹²

1. 昆明理工大学生命科学与技术学院,昆明 650500;
2. 昆明理工大学医学院,衰老与肿瘤分子遗传学实验室,昆明 650500

收稿日期:2014-08-18 出版日期:2015-04-20 发布日期:2014-12-08
通讯作者: 张继虹,博士,教授,研究方向：分子药理学。E-mail: zhjihong2000@126.com E-mail:sunshine_tongyang@163.com
作者简介:刘同阳,硕士研究生,专业方向：肿瘤药理学。E-mail: sunshine_tongyang@163.com
基金资助:
国家自然科学基金项目(编号：81260501,U1202221)资助

Synthetic lethal genes to mutant p53

Tongyang Liu^1,2,Haiqiang Guo²,Meiyan Zhu²,Yingze Huang²,Shuting Jia²,Ying Luo²,Jihong Zhang²

1. School of Life Science and Biotechnology, Kunming University of Science and Technology, Kunming 650500, China;
2. Laboratory of Molecular Genetics of Aging and Tumor, Medical College of Kunming University of Science and Technology, Kunming 650500, China

Received:2014-08-18 Online:2015-04-20 Published:2014-12-08

摘要/Abstract

摘要： 恶性肿瘤的靶向治疗已经成为现阶段肿瘤治疗的热点。随着人们对癌基因认知的加深,借助合成致死的方法靶向治疗肿瘤已成为针对肿瘤特异性治疗的新策略。p53基因突变在肿瘤的形成和发展过程中具有重要作用。因此,了解肿瘤中与突变型p53基因有合成致死关系的靶基因的作用方式,有助于指导由突变型p53基因诱发肿瘤的个性化治疗。与突变型p53基因具有合成致死关系的靶基因可分为细胞周期调控基因和细胞非周期调控基因,文章综述了这两类靶基因与突变型p53基因如何构成合成致死作用以及此作用的现实意义。

关键词: p53, 合成致死, 合成致死的交互作用, 肿瘤

Abstract: Targeted therapy has become a powerful approach for cancer treatment. Better understanding of oncogenes as well as synthetic lethal interactions with oncogenes will lead to new strategies for tumor-specific treatment. It is well known that mutant p53 plays an important role in tumorigenesis and tumor development. Thus, understanding the synthetic lethal relationship between p53 mutations and interacting genes in tumor is critical for the personalized treatments of p53 mutant tumors. Synthetic lethal genes to mutant p53 can be divided into cell cycle regulators and non-cell cycle regulators. This paper review show these two types of target genes contribute to synthetic lethal interactions with p53 mutations and potential applications of these interactions in anticancer therapy.

Key words: p53, synthetic lethality, synthetic lethal interactions, tumor

刘同阳,郭海强,朱美妍,黄英泽,贾舒婷,罗瑛,张继虹. 突变型p53与其合成致死基因的研究进展[J]. 遗传, 2015, 37(4): 321-326.

Tongyang Liu,Haiqiang Guo,Meiyan Zhu,Yingze Huang,Shuting Jia,Ying Luo,Jihong Zhang. Synthetic lethal genes to mutant p53[J]. HEREDITAS(Beijing), 2015, 37(4): 321-326.

参考文献

[1] Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Däbritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Pürfurst B, Walenta S, Mueller-Klieser W, Gräler M, Hummel M, Keller U, Buck AK, Dörken B, Willmitzer L, Reimann M, Kempa S, Lee S, Schmitt CA. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature , 2013, 501(7467): 421-425.
[2] Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov , 2011, 10(5): 351-364.
[3] Pessetto ZY, Yan Y, Bessho T, Natarajan A. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat , 2012, 134(2): 511-517.
[4] Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, Van Oers J, Edelmann W, Heukamp LC, Reinhardt HC. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC . Cancer Discov , 2014, 4(5): 592-605.
[5] Warrener P, Kim S, Williams SM, Biery M, Gordon M, Toniatti C, Cleary MA, Linsley PS, Carleton M. Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ. Apoptosis , 2012, 17(7): 691-701.
[6] Chan SL, Mok T. PARP inhibition in BRCA-mutated breast and ovarian cancers. Lancet , 2010, 376(9737): 211-213.
[7] Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA , 1989, 86(22): 8763-8767.
[8] Steele RJ, Lane DP. P53 in cancer: a paradigm for modern management of cancer. Surgeon , 2005, 3(3): 197-205.
[9] Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weslon A, Modali R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature , 1989, 342(6250): 705-708.
[10] Donehower LA, Harvey M, Slagle BL, Mcarthur MJ, Montgomery CA, Jr., Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature , 1992, 356(6366): 215-221.
[11] Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer , 2002, 2(8): 594-604.
[12] Liu J, Zhang C, Feng Z. Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai) , 2014, 46(3): 170-179.
[13] Kastan MB, Berkovich E. p53: a two-faced cancer gene. Nat Cell Biol , 2007, 9(5): 489-491.
[14] Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene , 1999, 18(55): 7883-7899.
[15] Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst , 1996, 88(14): 956-965.
[16] Rowley R, Hudson J, Young PG. The wee1 protein kinase is required for radiation-induced mitotic delay. Nature , 1992, 356(6367): 353-355.
[17] Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther , 2009, 8(11): 2992-3000.
[18] Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther , 2004, 3(3): 305-313.
[19] Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo , independent of p53 functionality. Mol Cancer Ther , 2013, 12(12): 2675-2684.
[20] Pappano WN, Zhang Q, Tucker LA, Tse C, Wang J. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells. BMC Cancer , 2014, 14: 430.
[21] Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev , 2009, 23(16): 1895-1909.
[22] Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X, Shi H. Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep , 2012, 28(6): 2247-2254.
[23] Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, Tokarz M, Adams BR, Wagner AF, Khalil A, Gilfor D, Golding SE, Deb S, Temesi DG, Lau A, O'connor MJ, Choe KS, Parada LF, Lim SK, Mukhopadhyay ND, Valerie K. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res , 2013, 19(12): 3189-3200.
[24] Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53- deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell , 2007, 11(2): 175-189.
[25] Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, Couvillon AD, Jacks T, Yaffe MB. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep , 2013, 5(4): 868-877.
[26] Razzak M. Basic research: MK2 and p53 - a lethal pairing. Nat Rev Clin Oncol , 2014, 11(1): 3.
[27] Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA , 2009, 106(10): 3964-3969.
[28] Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, Hughes A, Moy C, Liu-Sullivan N, Powers S, Bachman K, Jackson J, Weber B, Wooster R. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther , 2010, 9(7): 2079-2089.
[29] Tyagi S, Bhui K, Singh R, Singh M, Raisuddin S, Shukla Y. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells. Biochem Pharmacol , 2010, 80(9): 1326-1334.
[30] Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res , 1999, 59(15): 3663-3670.
[31] Meng X, Dizon DS, Yang S, Wang X, Zhu D, Thiel KW, Leslie KK. Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. Obstet Gynecol Int , 2013, 2013: 828165.
[32] Imai H, Kato S, Sakamoto Y, Kakudo Y, Shimodaira H, Ishioka C. High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H. Oncol Rep , 2014, 31(3): 1043-1050.
[33] Buzzai M, Jones RG, Amaravadi RK, Lum JJ, Deberardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res , 2007, 67(14): 6745-6752.
[34] Mizuarai S, Yamanaka K, Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res , 2006, 66(12): 6319-6326.
[35] Baldwin A, Grueneberg DA, Hellner K, Sawyer J, Grace M, Li W, Harlow E, Munger K. Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci USA , 2010, 107(28): 12463-12468.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

突变型p53与其合成致死基因的研究进展

Synthetic lethal genes to mutant p53

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	程香荣,胡兴琳,姜琦,黄星卫,王楠,雷蕾. 核糖体DNA转录的表观调控与肿瘤发生[J]. 遗传, 2019, 41(3): 185-192.
[2]	李鑫,李梦玮,张依楠,徐寒梅. 常用肿瘤基因分析方法及基于TCGA数据库的分析应用[J]. 遗传, 2019, 41(3): 234-242.
[3]	吴保军,王卓,董宇,邓宇亮,施奇惠. 肺癌恶性胸腔积液中稀有肿瘤细胞的鉴定与单细胞测序分析[J]. 遗传, 2019, 41(2): 175-184.
[4]	黎伟, 秦俊, 汪晖, 陈廖斌. 表观遗传生物标志物在人类疾病早期诊治中的研究进展[J]. 遗传, 2018, 40(2): 104-115.
[5]	王天工, 叶孟. m ⁶A甲基化与肿瘤研究进展[J]. 遗传, 2018, 40(12): 1055-1065.
[6]	吉新彦, 钟国轩, 赵斌. 哺乳动物Hippo信号通路分子机制研究进展[J]. 遗传, 2017, 39(7): 546-567.
[7]	鲁有望,王昆华. 结直肠癌原发与配对转移肿瘤遗传异质性研究进展[J]. 遗传, 2017, 39(6): 482-490.
[8]	叶仲杰,刘启鹏,岑山,李晓宇. LINE-1编码的逆转录酶在肿瘤形成过程中的作用[J]. 遗传, 2017, 39(5): 368-376.
[9]	王晨,李艳明,方向东. 肿瘤液态活检的研究进展及其临床应用[J]. 遗传, 2017, 39(3): 220-231.
[10]	吴文君, 王智华, 王卓, 邓宇亮, 施奇惠. 肺癌患者外周血中循环肿瘤细胞的快速分离与体外培养[J]. 遗传, 2017, 39(1): 66-74.
[11]	董彦娇, 逄越, 李庆伟. 长寿型啮齿类动物的抗肿瘤机制[J]. 遗传, 2016, 38(5): 411-417.
[12]	刘芳, 宋小珍, 谢华, 陈晓丽. 体细胞变异对神经系统常见肿瘤和发育异常类疾病的致病性[J]. 遗传, 2016, 38(3): 196-205.
[13]	刘茜,王瑾晖,李晓宇,岑山. 逆转录转座子LINE-1与肿瘤的发生和发展[J]. 遗传, 2016, 38(2): 93-102.
[14]	胡清霞,高昂,曾炜佳,王妍馨,董金堂,朱正茂. 高等哺乳动物LEM结构域蛋白家族的研究进展[J]. 遗传, 2015, 37(2): 128-139.
[15]	陈良榉,杨明,陈艳,孙华钦,许文明. miR-15b在内皮细胞的功能及其与血管相关性疾病的关系[J]. 遗传, 2015, 37(2): 121-127.